12:00 AM
 | 
May 08, 2000
 |  BC Week In Review  |  Company News  |  Deals

British Bio, ImmunoGen deal

BBG received exclusive rights in Europe and Japan to IMGN's huN901-DM1 tumor activated prodrug to treat small cell lung cancer. The companies will jointly develop the antibody, with IMGN responsible...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >